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Interest in extracellular vesicle biology has exploded in the past decade, since these microstructures seem
endowed with multiple roles, from blood coagulation to inter-cellular communication in pathophysiology.
In order for microparticle research to evolve as a preclinical and clinical tool, accurate quantification of
microparticle levels is a fundamental requirement, but their size and the complexity of sample fluids present
major technical challenges. Flow cytometry is commonly used, but suffers from low sensitivity and accuracy.
Use of Amnis ImageStreamX Mk II imaging flow cytometer afforded accurate analysis of calibration beads
ranging from 1 mm to 20 nm; and microparticles, which could be observed and quantified in whole blood,
platelet-rich and platelet-free plasma and in leukocyte supernatants. Another advantage was the minimal
sample preparation and volume required. Use of this high throughput analyzer allowed simultaneous
phenotypic definition of the parent cells and offspring microparticles along with real time microparticle
generation kinetics. With the current paucity of reliable techniques for the analysis of microparticles, we
propose that the ImageStreamX could be used effectively to advance this scientific field.
T
he ability of a cell to respond to external stimuli by producing extracellular vesicles (an umbrella term
including microparticles, exosomes and apoptotic bodies) is now appreciated1–3. These small structures, far
from being inert cellular debris, play roles in physiological processes such as coagulation4 and contribute to
the pathogenesis of a variety of diseases including atherosclerosis5,6, rheumatism7,8 and malignancy9.
Furthermore, these microparticles may be harnessed as therapeutic vectors, increasing potency of soluble pro-
teins10,11 and drugs12. However, knowledge on size, concentration, cell of origin, morphology and biochemical
composition of extracellular vesicles, such as microparticles, is limited, due to their sub-micrometer size and the
intrinsic limitations in methods applied for their characterization1.
Flow cytometry represents the mainstay of microparticle measurements in the literature, probably due to its
ease-of-access. Recent developments in this field have progressed flow cytometry towards a standard for micro-
particle research13,14, yet the resolution of most commercially available cytometers remains around 500 nm. The
methods adopted, such as calibration of the forward-scattering intensity using polystyrene microspheres is beset
with issues regarding the refractive index relationship between size andmaterial15. The use of high-resolution flow
cytometry has enhanced the measurements obtainable using this method, and the Apogee A40 flow cytometer is
able to resolve cell derived particles down to 400 nm in diameter16 using the forward scatter detector.
Advances in standard flow cytometric analysis are slow to be adopted.Whilst fairly robust for themeasurement
of cells, the forward scatter detector gives a variable signal between instruments, affecting reproducibility between
laboratories. It is the most alignment-critical detector within the cytometer and can be affected by multiple
variables, including mismatches in the refractive index between the sheath fluid and sample, beam geometry,
polarization, stop position and collection angle. The forward scatter position of microparticles of different sizes
does not therefore follow their relative order in physical size. Furthermore, resolving twomicroparticles requires a
difference in size between them of at least 280 nm17. In contrast, side-scatter or ‘‘right-angled light scatter’’ shows
good correlation to size. This is because all instruments aim for maximal light collection and are therefore
designed to achieve similar numerical apertures. This makes the side-scatter a more robust discriminator,
especially between instruments17. Side-scatter information teamed with fluorescence labeling allows further
discrimination between cell fragments, noise and true microparticles. Setting the axis parameters to side-scatter
versus fluorescence allows the more accurate placement of 0.5 mm beads and eliminates background noise from
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A second practical obstacle in the multi-labeling of microparticle
samples is coincidence. The fluidics of flow cytometers is designed
for passing single cells in a hydro-dynamically guided stream
through the cuvette. Single isolated polymorphonuclear cells, as
one example, occupy 630 mm318, whereas microparticles are much
smaller, resulting in sub-optimal hydrodynamic focusing. This
allows multiple microparticles to be interrogated simultaneously
and processed as a single event, especially in concentrated samples
where double, triple, or more, false-positive single events may be
recorded. Performing dilutions of the sample so that microparticles
travel more rarely through the cuvette may aid in the reduction in
coincidence, but conversely it would increase inter-sample variability
further.
Other measurement assays are available for the analysis of micro-
particles, including optical methods such as nanoparticle tracking
analysis, and non-optical methods like transmission electron micro-
scopy, impedence-based measurements and Raman spectroscopy.
Caveats to all of these techniques exist. Nanoparticle tracking ana-
lysis has a functional measurement cut-off at 1 mm, skewing sizing
results towards small particles. Transmission electron microscopy,
especially teamed with cryo-preparation has yielded superior results
on the sizing, morphology and biochemical composition of micro-
particles1 but requires high-level skill and expertise for sample pro-
cessing and analysis. It is not a technique that can be rapidly deployed
in many laboratories and, even less, clinical settings.
We have used the ImageStreamX Mk II imaging cytometer (there-
after ISX for short) for the detection of microparticles for the first
time. The overwhelming advantage of this technology is the visual
interrogation of each event passing through the flow cell. Even below
the physical optical resolution cut-off of 200 nm, the ISX can detect
fluorescent signals of otherwise undetectable microparticle popula-
tions. We have evaluated presence of microparticles in a variety of
blood-based samples, and provided phenotypic quantification of
healthy plasma microparticles to demonstrate the superior usability
of this technique. Herein, we describe for the first time the temporal
kinetics of real-time microparticle generation from neutrophils and
explored the role of the cytoskeleton in their production.We propose
the use of this imaging cytometer will advance extracellular vesicle
research, and has the potential to allow wide-scale adoption for the
enumeration ofmicroparticles from archived frozen plasma samples.
Results
We have used the high sensitivity imaging cytometer, the Amnis
ImageStreamX Mk II (ISX) for characterization of microparticle
populations. This cutting edge instrument uses proprietary charge-
coupled devices (CCDs) instead of photomultiplier tubes and cap-
tures up to 12 images (10-colour) of each event as it passes through
the flow cell. ISX was designed to allow the co-localization of sub-
cellular particles within cells and is equipped with a X60 objective in
order to do this, which subsequently makes it amenable to micro-
particle detection and analysis. Acquisition parameters can be deter-
mined by a huge variety of physical parameters rather than just size,
complexity and fluorescence intensity. In terms of microparticle
research, this analyzer represents important advancements in sample
detection and measurement. Firstly, each event recorded is paired
with a bank of images generated for each single event. Dot plots and
image galleries are therefore searchable and can be used to corrob-
orate event identity by eye. Multicolor staining can be further
exploited for accurate identification of various subpopulations.
Initially, we compared the sensitivity of the ISX with a commer-
cially available, standard flow cytometer, the BD LSRFortessa, using
fluorescent 20 nm to 1 mm latex calibration beads. Importantly, we
were able to detect 20 nm beads using the ISX that were completely
undetectable using the LSRFortessa. We found the best resolution of
the two larger bead populations using the fluorescence intensity
plotted against side-scatter for both machines (Figure 1a,b). We
could also detect a larger number of 0.1 mm beads using the ISX,
but more of this population was lost within the machine noise of
the LSRFortessa. By contrast, no noise events were detected using the
ISX. Sizing with ISX according to area or diametermeasurements were
somewhat less useful, evenwhenmeasured on the fluorescence chan-
nel with stringent masking. This is because, at such high magnifica-
tion, a single pixel represents an area of 0.3 mm2, which is a large
proportion of a 0.5 mmdiameter bead ormicroparticle. Fluorescence
signals also suffer from significant haloing, leading to an overestima-
tion of particle size (Figure 1c). Nevertheless, the side-scatter mea-
surements still corresponded to the relative size of the bead
populations (Figure 1a, see histograms), and that the 20 nm beads
were detectable by their fluorescent signal suggests that the enumera-
tion of microparticles of all sizes is feasible. In contrast, the
LSRFortessa struggled with forward-scatter laser measurements,
and the beads could not be placed according to size, and the smallest
beads were undetectable.
Furthermore, themachine’s advanced fluidics control and reliabil-
ity of the Objects per ml feature could be demonstrated by serial
dilution of microparticle samples. Indeed, Pearson correlation coef-
ficients close to 1 were achieved for three donors between sample
dilution and microparticles per ml (see Supplementary Fig. S1
online). Testament to the fine fluidics control of the ISX, coincidence,
or ‘‘swarms’’ of microparticles or beads were also not encountered at
any dilutions of the sample acquisition.
Next, we tested ISX for microparticle detection in complex bio-
logical fluids such as platelet-poor and platelet-rich plasma, whole
blood, and the supernatants of stimulated isolated neutrophils
(Figure 2). Uniquely among analyzers used for detecting micropar-
ticles, the parent cells do not need to be removed before acquisition.
By staining with BODIPY-maleimide dye, we could identify leuko-
cyte, platelet, erythrocyte and microparticle populations without the
need for phenotypic markers. Microparticles could be detected in all
samples, at different quantities, and differed from the internal cal-
ibration beads (of similar size and BODIPY-Maleimide fluorescence
intensity) due to their high side-scatter signal. BODIPY-Maleimide
staining was adopted for these experiments as labeling is almost
instant, and the cells do not require washing before sample acquisi-
tion. As a result, these speed beads also take up some of the dye and
fluoresce, but still form discrete populations that can be gated out of
the analysis. Advantageously, each event gated could be visually
corroborated by interrogation of the images generated for each event
(Figure 2b) thus, the largemajority of events could be placed in one of
each of the gates.
As our analyses had relied only on pan-labeling of cells andmicro-
particles by BODIPY-Maleimide, next we investigated whether we
could simultaneously interrogate the activation status of TNF-a sti-
mulated neutrophils using anti-CD66b, CD62L and CD11b staining,
and whether these antigens could be detected on the offspringmicro-
particles (Figure 3). As expected, neutrophils were highly positive for
CD66b and with TNF-a stimulation shed a proportion of their L-
selectin (CD62L), whereas CD11b was highly expressed (Figure 3a).
Furthermore, the microparticles also displayed a high degree of
CD66b positivity, and their CD62L expression overlapped with those
of neutrophils and CD11b was also expressed. Figure 3b displays
representative images; the uppermost neutrophil panel shows a neu-
trophil with intermediate CD66b, CD62L and CD11b expression,
suggesting incomplete activation, the neutrophil in the lowest panel
displays higher CD66b andCD11b expressionwith a complete loss of
CD62L suggesting full activation.
As Timar, et al.19 had demonstrated that differential stimulation of
neutrophils leads to different numbers of microparticles being gen-
erated, we used the ISX to enumerate the number of microparticles
produced during cell activation (Figure 4a). This analyzer has syringe
driven fluidics and achieves a high level of control over the flow rate
passing through the flow cell using the speed beads for calibration.
www.nature.com/scientificreports
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Therefore it can achieve accurate concentration measurements.
Following 20-min stimulation of neutrophils with TNF-a (50 ng/
ml), IL-8 (50 ng/ml) and leukotriene B4 (LTB4; 10 nM), micropar-
ticle production doubled compared with resting cells (TNF-a 6.96 1
vs. vehicle 2.1 6 0.4 3 107 microparticles/ml from 2.5 3 106 neu-
trophils in 50 ml, N53; P,0.01 with Repeated measures ANOVA
and Bonferroni post-test; LTB4 6.1 6 1.5 and IL-8 6.6 6 0.6 vs.
vehicle 2.16 0.43 107 microparticles/ml from 2.53 106 neutrophils
in 50 ml, n53; P,0.05 with Repeated measures ANOVA and
Bonferroni post-test). The approximate diameter of the offspring
microparticles did not alter upon stimulation (Figure 4b).
To explore microparticle generation further, ISX analysis was
employed to quantify neutrophil microparticle production in real
time. As ISX analysis allows parallel analysis of both parent neutro-
phils and offspring microparticles in the same sample collection, it
proved a powerful tool for assessing the kinetics of microparticle
formation. ISX analysis of neutrophils labeled with BODIPY-
Maleimide and stimulated with TNF-a (50 ng/ml) immediately
prior to acquisition revealed that the rate of neutrophil microparticle
production was significantly higher when the cells were stimulated
with TNF-a (50 ng/ml) than that of resting cells over a 45-minute
period (Figure 4c,d; P,0.001 with Mixed-model ANOVA). It was
possible to observe budding neutrophil microparticles during this
analysis (Figure 4e) and therefore ISX analysis of both parent and
offspringmicroparticles, concurrently within one sample, lends itself
to multiple applications.
The cytoskeletal control of microparticle production was next
assessed. Microparticle generation requires cytoskeletal re-organiza-
tion in the origin cell. We applied distinct compounds to dissect the
involvement of specific intracellular events in microparticle forma-
Figure 1 | Sizing beads (1 mm, 0.5 mm, 0.1 mm and 0.02 mm) are differentiated using ImageStreamX Mk II imaging cytometer, which has superior
detection compared to the BDLSRFortessa. Fluorescent latex beads of 1 mm, 0.5 mm, 0.1 mmand 0.02 mmwere diluted in double-sterile filtered PBS and
acquired using ISX at X60magnification. (a) TheDark Field Scattering intensity was plotted against fluorescence intensity (Channel 02 andChannel 11 for
0.02 mm beads; left hand panel), area (middle panel) or diameter (right hand panel), with measurements taken from the fluorescence area mask (70%
saturation), with corresponding histograms shown. (b) The same bead samples were acquired using the BD LSRFortessa with low flow rate. Equivalent
plots and histograms are shown. The presence of machine noise is indicated in grey, which is notably not present in the ISX. The smallest beads, 0.02 mm
(orange), were completely undetectable using the BD LSRFortessa. (c) Representative images of beads of each size showing fluorescence intensity
and brightfield images from brightfield camera 1 and 2, generated using the ISX. Although the 0.02 mmbeads were detectable using the ISX, they could not
be seen in the corresponding image banks.
www.nature.com/scientificreports
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tion, using Jasplakinolide and cytochalasin D to stabilize and desta-
bilize the actin cytoskeleton, respectively (Figure 5a–c). We targeted
the interaction of actin and myosin using blebbistatin (non-muscle
myosin II inhibitor preventing cell contraction allowing blebbing)
andML-7 (a selectivemyosin light-chain kinase inhibitor; Figure 5d–
f) and finally chelated the intracellular calcium of neutrophils with
BAPTA-AM before stimulation with TNF-a (50 ng/ml; Figure 5g–i)
to induce microparticle shedding. As neutrophil viability was not
significantly affected by the drugs tested (data not shown), the off-
spring microparticles were isolated by sequential centrifugation to
deplete the cells, loadedwith BODIPY-Maleimide dye and quantified
using ImageStreamX analysis. Jasplakinolide, which inhibits actin
depolymerization and cytochalasin D, which inhibits actin polymer-
ization, both had significant effects on the number of microparticles
produced by neutrophils without altering the size or shape of the
microparticles generated. Jasplakinolide significantly inhibited
microparticle production induced by TNF-a stimulation: 0.9 6 0.3
vs. 1.9 6 0.5 3 107 microparticles/ml (n54; P,0.05 with Two-way
ANOVA and Bonferroni post-test) whereas cytochalasin D increased
microparticle production in unstimulated (2.6 6 0.2 vs. 0.8 6 0.3 3
107 microparticles/ml, P,0.01 with Two-way ANOVA and
Bonferroni post-test) as well as TNF-a stimulated neutrophils (3.0
6 0.1 vs. 1.9 6 0.5 3 107 microparticles/ml, P,0.05 with Two-way
ANOVA and Bonferroni post-test), and induced the highest amount
of microparticle shedding of all the drugs tested. These data confirm
the role of the actin cytoskeleton in the regulation of microparticle
production, as enhanced actin polymerization inhibits microparticle
shedding and disruption of the cortical actin network enhances the
number of microparticles generated. In contrast, treatment with
drugs that inhibit non-muscle myosin motors did not significantly
modify microparticle numbers from seven individual blood donors
(Figure 5d). The size of the microparticles was also not altered
(Figure 5e,f). This suggests that microparticle formation can occur
in the absence of myosin-induced cell contraction.
Intracellular fluxes of calcium are known to be heavily involved in
the events surrounding microparticle formation and shedding from
initial receptor ligation up to the rearrangement of cytoskeletal com-
ponents and phospholipid reorganization. Calcium fluxes also
recruit annexins to the plasma membrane to achieve membrane
cleavage and microparticle release2. Intracellular calcium chelation
using BAPTA-AM significantly inhibited microparticle production
compared to stimulation with TNF-a (0.3 6 0.2 vs. 1.9 6 0.5 3
107 microparticles/ml, N56; P,0.05 with Two-way ANOVA and
Bonferroni post-test) as expected (Figure 5g).
Finally, we quantified the number of circulating microparticles in
healthy donor samples and elucidated their cell of origin (Figure 6a
and b). The attractive possibility of using circulating microparticle
levels as putative biomarkers for disease states requires the thorough
testing of healthy donors to define ‘‘normal’’ limits, and agreement
on the number of circulating microparticles is lacking13,20, probably
due to the variety in techniques applied. We generated platelet-poor
plasma samples from 6 healthy donors and interrogated their cell of
origin using conjugated antibodies to antigens previously reported to
be shed onto microparticles21–27. The entire microparticle population
was labeled by the addition of BODIPY-Maleimide dye and double-
positive events expressed as a percentage of the BODIPY-Maleimide
labeled population (Figure 6a and b). Thus, in six distinct prepara-
tions themajority of circulatingmicroparticles were observed to be of
erythrocyte origin (37.5%), then of platelet (24.3%), leukocyte (12%),
and endothelial cell origin (6.6%). We subtyped the leukocyte popu-
lation further and found that neutrophil microparticles comprised
the largest proportion of leukocytemicroparticles (3.6%) thenmono-
Figure 2 | Distinct populations of cells, platelets and microparticles can be differentiated within whole blood, plasma and isolated cells. (a) Platelet-
poor and platelet-rich plasma, whole blood and isolated TNF-a-stimulated polymorphonuclear (PMN) cell samples were labeled with BODIPY-
Maleimide dye prior to acquisition on the ISX. Pink gates denote speed beads (and their aggregates), used as internal calibration for the cytometer; orange
gate denotes erythrocytes; blue gate denotes leukocytes (neutrophils); green gate denotes platelets and aqua gate denotesmicroparticles, that appear as low
scatter, low fluorescence intensity. (b) Representative images from each of the cell population gates.
www.nature.com/scientificreports
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cyte (3.4%) and lymphocyte microparticles (0.9%). The sum of the
leukocyte-positive microparticle proportions equaled 8%; lower than
the CD451 leukocyte microparticle population at 12%. This discrep-
ancy could represent a proportion of leukocyte microparticles of an
unaccounted origin, or that not all antigen transfer onto micropar-
ticles is equal. In terms of microparticle counts, we found that the
average total microparticle count per milliliter of platelet poor
plasma was 2.5 3 106 (Figure 6c).
Discussion
At present, the high-throughput, high-accuracy enumeration and
measurement of microparticles requires multiple techniques for pro-
duction of robust and reproducible data. For example, commercial
flow cytometers have a lower-limit of detection that excludesmany of
the smaller particles from sample analysis, and is of low accuracy16.
Nanoparticle tracking analysis, which measures the Brownian
motion of particles in suspension providing accurate quantification
of microparticle number and size, has an upper detection-limit cut-
off at 1 mm. The availability of this system with multiple color label-
ing is also not currently available. Specialist techniques such as
atomic force microscopy, impedance-sensing and Raman spectro-
scopy also have caveats such as the relative expense and do not lend
themselves to wider-reaching applications. The gold standard of
cryo-transmission electron microscopy provides the most accurate
data, but requires expert implementation1. We propose here that the
ImageStreamX imaging cytometer can give accurate enumeration,
allowing simultaneous detection of larger ($1 mm) and smaller
(approximately 20 nm) microparticle populations and parent cells.
With this technology, kinetics of microparticle production could be
accurately measured for the first time.
The ISX was superior at detecting smaller sized latex beads com-
pared to the LSRFortessa, and analysis using the ISX benefits from the
ability to visually interrogate each individual event passing through
the flow cell, allowing corroboration of events presented in dot plots
and histograms. Noise within the analyzer was also minimal com-
pared to the LSRFortessa, due to both the multiple-interrogation of
each event, and the self-sterilization and cleaning system within the
setup. Furthermore, sample preparation, depending on the applica-
tion required, can range from minimal, i.e. simple fluorescent dye
labeling, to extensive, with panels of multiple antibodies. Here, we
demonstrated the detection of microparticles in whole blood using
BODIPY-Maleimide labeling, which could also be applied to plasma
and isolated cells. We then demonstrated the applicability of pheno-
typing parent neutrophils and their offspring microparticles simul-
taneously. None of these experimental protocols have been possible
before.
Microparticles bear antigens from their parent cells, allowing
phenotypic measurements to be made about their parent cell of
origin28. Not only did neutrophil microparticles express the canon-
ical CD66b neutrophil marker used formicroparticle phenotyping in
previous studies, but they also bore CD62L and CD11b. In these
analyses we could quantify simultaneously the activation status of
the parent cells and their offspringmicroparticles. It was also possible
to identify the proportions of microparticle subpopulations from
healthy plasma. As microparticle analysis has a potential clinical
use as a biomarker for a variety of diseases, normal limits need to
Figure 3 | Simultaneous analysis of parent cell and microparticle phenotype. Isolated neutrophils were stimulated with TNF-a (50 ng/ml) for 20
minutes then stained on ice with anti-CD66b, anti-CD62L and anti-CD11b before acquisition using ISX. (a) Histograms of CD66b, CD62L and CD11b
intensity of offspringmicroparticles and neutrophils, compared to isotype control (pink). (b) Representative images of labeled neutrophils (upper panel)
showing increasingly activated phenotypes, and offspring microparticles (lower panel) with examples of double and triple-positive events.
www.nature.com/scientificreports
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be defined, thus detection of microparticles in platelet-poor plasma
opens up the opportunity for use of frozen archived samples for
microparticle analysis. We demonstrate here that quantification of
microparticles (with or without defining their cell of origin) is pos-
sible with minimal sample preparation.
The real-time temporal kinetics of microparticle production has
not before been studied in neutrophils. Static measurements of
microparticle number have been made using aliquots of cerebral
vascular endothelial cell line supernatant taken and tested by flow
cytometry29 or by spectrophotometric analysis of the supernatants of
adherent glial cells stimulated with an ATP mimetic30. During glial
cell culture, stimulation with ATP induced a plateau of microparticle
production after 20 minutes, and with time-lapse microscopy,
microparticle shedding could be observed (but not quantified) 1–2
minutes after stimulation30. Reported here, analysis of freshly
isolated neutrophils in suspension, stimulated with TNF-a and
analyzed in real-time over 45 minutes showed an increase in the rate
of microparticle production compared to resting cells. Although a
plateau in microparticle production was not reached over this time-
course, the limiting factor of data acquistion was the file size gener-
ated during such an experiment. This assay could be translated to
explore the real-time kinetics of microparticle generation in com-
bination with cytoskeletal inhibitors, such as those used in single
time-point experiments.
The process ofmicroparticle production and release (vesiculation)
requires the dynamic coordination of cellular components for effec-
tive destabilization of the plasma membrane. It has been observed
that during microparticle formation in cerebral microvascular
endothelial cells, there is dissolution of the cortical F-actin network,
followed by prominent actin stress fiber formation, and redistribu-
tion of vinculin to the newly formed fibers29. Consistent with these
findings, our data show that treatment of neutrophils with jasplaki-
Figure 4 | Isolatedmicroparticles can be quantified and the real-time generation of neutrophil microparticles can be assessed with ISX. (a) Neutrophils
were labeled with BODIPY-Maleimide, then microparticles were generated using TNF-a (50 ng/ml), IL-8 (50 ng/ml) or leukotriene B4 (10 nM) and
enumerated using ISX. (b)Microparticle diameter was assessed using the Channel 02 fluorescence parameter with a 75% stringent mask applied. Data are
shown as mean 6 SEM of 3 blood donors. *P,0.05 and **P,0.01 using repeated measures ANOVA and Bonferroni post-test. (c) Neutrophils were
isolated from three healthy donors, immediately labeled with BODIPY-Maleimide dye and stimulated with TNF-a (50 ng/ml) followed by immediate
acquisition for 45 minutes. The rate of microparticle production was inferred by gating the microparticle population, applying the ‘‘Objects per second’’
feature and plotting against time. (d) Summarized data from the three donors, P,0.001withMixed-model ANOVA. (e) Representative ISX gallery images
of neutrophil microparticles budding at the times indicated.
www.nature.com/scientificreports
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nolide, which promotes actin polymerization and stabilizes actin
filaments into an amorphous mass, inhibits microparticle release.
In contrast, treatment with cytochalasin D, a potent inhibitor of actin
polymerization, increasing the cellular membrane fluidity, increases
microparticle release. As demonstrated with the ISX, this increase in
microparticle shedding was not accompanied by concomitant
increases inmicroparticle size. Disrupting the functions of non-mus-
cle myosin to disrupt cell contraction withML-7 and blebbistatin did
not lead to alterations in the number of microparticles shed. In
addition, microparticle release, along with many cellular processes,
is calcium-dependent31. Intracellular calcium chelation led to block-
ade of microparticle shedding. This suggests that regulated micro-
particle formation is reliant on the ability of actin to polymerize and
depolymerize in a coordinated fashion. Further real-time studies on
the production of microparticles under conditions of cytoskeletal
rearrangement inhibition will uncover further regulation.
We have enumerated microparticles from the plasma of 6 healthy
human volunteers, but further work to expand the cohorts of normal
subjects to define the ‘‘normal’’ limits of microparticle phenotypes is
required. The ultimate goal of microparticle analysis for use in
detecting pathology in clinical settings would be the direct enumera-
tion of both leukocyte subsets and the microparticles they produce32.
We provide evidence for the first time that this is achievable using the
ISX. We were able to phenotypically identify the majority (.90%) of
microparticles within the plasma samples; full identification of the
remainder of ‘‘unknown’’ microparticles is, however, likely to remain
asymptotic. As any cell type is capable of producing microparticles
(the machinery required for microparticle release is likely to be sim-
Figure 5 | The mode of microparticle shedding is largely actin-dependent and requires intracellular calcium. Neutrophils isolated from 6 healthy
donors were treated with drugs that interfere with actin polymerisation (Jasplakinolide, 1 mM and Cytochalasin D, 2 mM; panels a–c) or myosin-
dependent cell contractility (Blebbistatin, 10 mM and ML-7, 20 mM; panels d–f) and a calcium chelator (BAPTA-AM, 20 mM; panels g–i) before the
addition of TNF-a (50 ng/ml) for 20minutes. Cells were removed by gentle centrifugation, andmicroparticles were stainedwith BODIPY-Maleimide dye
before acquisition using ISX. Offspring microparticles were enumerated (panels a, d and g) and the perimeter (panels b, e and h) and diameter (panels c,f
and i) were measured following the application of a fluorescence intensity mask applied to Channel 02 (BODIPY-Maleimide fluorescence) following
erosion to 70% to ensure tight masking. *P,0.05, **P,0.01 and ***P,0.001 using Matched Two-way ANOVA with Bonferroni post-test.
www.nature.com/scientificreports
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ilar to endosomal and vesicular transport), the characterization of the
origin of microparticles will require extensive exploration in the
biology of this field, even with advances in technology. Clearly, this
analyzer has many potential diagnostic applications, but this novel
combination of cellular and microparticle enumeration makes the
ISX a powerful tool, for the future of microparticle research.
Methods
Materials. ImageStreamXMk II was fromAmnis Corporation, Seattle, WA, USA and
the BD LSRFortessa from BD Biosciences (San Jose, California). All chemicals and
reagents were purchased from Sigma-Aldrich, Poole, UK, unless otherwise stated,
including 0.1 mm (L1528-1ML), 0.5 mm (L1403-1ML) and 1 mm (L1278-1ML) latex
calibration beads, and the cytoskeletal inhibitors. Crimson fluorescent 0.02 mm
FluoSpheres (F-8782), Dextran (MW 450,000–650,000), cytochalasin D, histopaque
1077 and BODIPY FL N-(2-aminoethyl)maleimide) (FITC and Texas Red BODIPY-
Maleimide) were purchased from Life Technologies, Invitrogen, Paisley, UK.
Leukotriene B4 was purchased from Cayman Chemical, Ann Arbor, MI, USA.
Antibodies were used as follows: anti-humanCD66b-PE (BioLegend, cloneG10F5) at
0.25 mg/ml with isotype IgM (BioLegend, cloneMM-30); anti-human CD11b-pacific
blue (BioLegend, clone ICRF44) used at 10 mg/ml with isotype IgG1 (BioLegend,
clone MOPC-21); anti-human CD62L-PE/Cy5 (BioLegend, clone DREG-56) used at
1 mg/ml with isotype IgG1 (BioLegend, cloneMOPC-21); anti-human CD235a-FITC
(eBioscience, clone HIR2) used at 0.25 mg/ml with isotype IgG2b (eBioscience, clone
eBMG2b); anti-human CD146-APC (BioLegend, clone SHM-57) used at 0.5 mg/ml
with isotype IgG2a (BioLegend, clone MOPC-173); anti-human CD45-PerCP/Cy5.5
(eBioscience, clone HI30) used at 0.5 mg/ml with isotype IgG1 (eBioscience, clone
P3.6.2.8.1); anti-human CD41-FITC (BioLegend, clone HIP8) used at 0.25 mg/ml
with isotype IgG1 (BioLegend, clone MOPC-21); anti-human CD14-PE/Cy7
(BioLegend, clone HCD14) used at 2 mg/ml with isotype IgG1 (BioLegend, clone
MOPC-21); anti-human CD66b-FITC (AbD Serotec, clone 80H3) used at 1/100
dilution with isotype IgG1 (BioLegend, clone MOPC-21); anti-human CD3-APC
(BioLegend, clone UCHT1) used at 0.5 mg/ml with isotype IgG1 (BioLegend, clone
MOPC21).
Methods. Preparation of calibration beads. Latex beads were diluted 1515,000 in
double-sterile-filtered (0.22 mm) PBS after 5-minute sonication and vortexing to
disperse. Samples were acquired immediately with either the BD LSRFortessa at low
flow rate, or using ISX as described below.
Preparation of samples. All volunteers gave written informed consent to blood col-
lection and the procedure was approved by the East London & The City Local
Research Ethics Committee (Rec Ref. 05/Q0603/34 ELCHA, London, United
Kingdom) in accordance with theWorld Health Organization guidelines on drawing
blood. Peripheral blood fromhealthy donors was collected by intravenouswithdrawal
and added to sodium citrate solution to prevent coagulation. Neutrophils were iso-
lated from blood via density centrifugation on a Histopaque 1077 gradient (Sigma
Aldrich) according to the manufacturer’s instructions. In detail, blood (60 ml) was
taken from healthy volunteers using a 21G butterfly needle with tourniquet applied
and anticoagulated with 0.32%w/v sodium citrate.Whole bloodwas stained as below.
Platelet-rich and platelet-poor plasma were generated by centrifugation at 3003 g for
20 minutes to pellet the cells, then the platelet rich plasma recovered, and platelets
depleted by a third centrifugation at 10,000 3 g for 2 minutes. Neutrophils were
isolated from whole blood using dextran sedimentation followed by density gradient
separation as follows: blood was centrifuged at 130 3 g for 20 minutes at room
temperature to sediment the cells. Platelet rich plasma was removed before 10 ml
phosphate-buffered saline (PBS) was carefully layered over the cell suspension, to
avoid mixing. Dextran (from Leuconostoc, molecular weight 450,000 to 650,000; 6%
w/v, 8 ml) was gently layered onto the PBS. The tubes were inverted gently to mix the
Figure 6 | Plasma microparticles from healthy human donors are largely derived from erythrocytes and platelets. (a) Platelet-poor plasma was
generated from 6 healthy donors and stained to determine the microparticle cell of origin using CD235 (erythrocyte), CD41 (platelet), CD45 (leukocyte)
and CD146 (endothelial cells) markers. (b) Leukocyte microparticles were further phenotyped to determine their cell of origin using CD14 (monocyte),
CD66b (neutrophil) and CD3 (lymphocyte) markers. Data are expressed as percentage BODIPY-Maleimide positive events and shows mean (line) and
individual raw values. Below are representative images of events from the gallery. (c) Table shows absolute counts 6 SEM of N56 donors.
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cell suspension with the PBS and dextran. After 20 minutes the leukocyte rich layer
was carefully collected, and layered over 10 ml Histopaque 1077 in a fresh 50 ml
falcon tube and centrifuged for 30 minutes at room temperature at 450 3 g.
The supernatant was aspirated and the red blood cells were lysed through hypo-
tonic shock with 9 ml ice-cold ultrapure distilled water. Isotonicity was quickly
restored by adding 1 ml 10x Hanks Balanced Salt solution. Granulocytes were pel-
leted at 300 3 g for 10 minutes at room temperature, the supernatant was aspirated
and the granulocyte pellet was resuspended in phenol red-free RPMI and adjusted to
2 3 107/ml for stimulation.
For fixed-time microparticle generation, cells (2 3 107/ml) were stimulated with
TNF-a (50 ng/ml, Sigma), IL-8 (50 ng/ml, Peprotech), LTB4 (10 nM, Cayman
Chemical) or vehicle (PBS) for 20 minutes at 37uC before placing on ice to arrest
microparticle production. Cell suspensions were then either processed for
ImageStreamX analysis or their neutrophils were pelleted by centrifugation at 4500 3
g for 15 minutes at 4uC followed by a second centrifugation at 13,200 3 g at 4uC for 2
minutes. Samples were resuspended in phenol-red free RPMI before proceeding to
processing for ImageStreamX analysis.
For real-time microparticle generation, freshly isolated neutrophils were resus-
pended at 1 3 106 cells/ml in phenol red-free RPMI and labelled with BODIPY-
Maleimide dye (2.5 mM) 2 minutes prior to sample acquisition, then the sample
loader lowered. TNF-a (50 ng/ml) was added immediately prior to placing the
eppendorf into the sample loader and loading. Acquisition of events was started
immediately, and the events appearing in the microparticle population gate collected
on low speed/high sensitivity for 45 minutes.
In other experiments, the phenotype of neutrophils was assessed. Isolated neu-
trophils were stimulated with TNF-a (50 ng/ml) for 20 min at 37uC then stainedwith
CD66b-PE, CD62L-PE/Cy5 and CD11b-pacific blue for 30 min on ice. Samples were
then acquired with ISX.
For circulating plasma microparticle phenotyping experiments, 5 ml platelet poor
plasma PPP was diluted 152 with human immunoglobulin gamma (8 mg/ml final;
Sigma) to block Fc receptors for 10 minutes. Samples were then stained with the
following antibodies: 50 mM BODIPY-Maleimide – Texas Red, CD235-FITC
(erythrocyte marker), CD45-PerCP/Cy5.5 (leukocyte marker), CD146-APC
(endothelial marker), CD41-FITC (platelet marker), CD14-PE/Cy7 (monocyte
marker), CD66b-FITC (neutrophil marker), CD3-APC (lymphocyte marker).
Appropriate isotype and single stain controls were used. Samples were stained in the
dark at room temperature for 30 minutes before acquisition with ISX.
Effect of cytoskeletal inhibitors. To investigate the intracellular machinery required for
microparticle generation, freshly isolated neutrophils were treated for 10 minutes
with Cytochalasin D (2 mM), Jasplakinolide (1 mM), Blebbistatin (10 mM), ML-7
(20 mM) or 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis(a-
cetoxymethylester) (BAPTA-AM; 20 mM) at 37uC. Neutrophils were then plated into
96-well plates and centrifuged at 200 3 g for 30 seconds at room temperature,
followed by washing in PBS. Cells were then stimulated with TNF-a (50 ng/ml) or
vehicle (PBS) for 20minutes. Supernatants were collected by centrifugation at 35003
g to deplete neutrophils, stained with BODIPY-Maleimide dye as above and acquired
with the ImageStreamX Mk. II to quantify microparticle number and size.
Analyses on the ImageStreamX MkII. All samples were acquired on an ImageStreamX
MkII imaging cytometer, X60magnification; with low flow rate/high sensitivity using
INSPIRE software. In order to detect microparticles in the samples, and to visualize
the speed beads running throughout acquisition, the setting ‘‘Hide Beads’’ under the
Advanced.Acquisition menu had to be unchecked. The percentage of BODIPY-
Maleimide1 microparticles positive for each lineage marker was measured.
The instrument and INSPIRE software were set up as follows: Channels 01 (bright
field), 06 (bright field 2) and channel 12 (scattering channel), plus fluorescence
channels required. Magnification was 60X, providing a pixel size of 0.3 mm2 and the
lasers 488 and 745 activated for fluorescence and side-scatter, respectively; with or
without 405 and 642 laser activation. The flow rate was set to low speed/high sens-
itivity and stream alignment was adjusted where necessary. To obtain a collection
gate, a scatter plot of BODIPY-Maleimide (channel 02 for FITC-conjugated, channel
04 for Texas Red conjugated) fluorescence intensity was plotted against side scatter
(channel 12) side scatter intensity. This allows discrimination of speed beads, which
are used as an internal calibrator for themachine’s image capture system to determine
the flow rate. These speed beads run continuously throughout both sample collection
and while the machine is idle, but could be completely excluded from microparticle
analysis as they form a discrete high-scatter intensity, low channel 02 fluorescence
intensity population.
BODIPY-Maleimide labeled microparticles appeared as a low-scatter, low to mid
fluorescence intensity, and any contaminating cells appear as high fluorescence
intensity. Each gated population was interrogated via the image gallery to determine
the upper and lower limits of microparticle size and shape. Microparticles char-
acteristically appear as small, spherical FITC or Texas Red-fluorescent points, and can
be discriminated from cells, which are much larger, or cellular debris, which is not
uniformly spherical.
For real-time neutrophil microparticle generation experiments, the upper collec-
tion event gate was set to 1 3 106 to prevent premature termination of sample
acquisition. For simple enumeration of pre-prepared microparticle samples, the
acquisition cut-off was set to 10,000. To determine the concentration of the sample,
IDEAS software was used. Raw image files with the entire number of events were
opened. A scatter plot showing channel 02 fluorescence intensity plotted against
scattering intensity of channel 12 was generated and a microparticle gate re-applied
and inspected visually to exclude inappropriate events. The gate was adjusted where
necessary. The objects/mL feature was added to the analysis area, and applied to the
microparticle gate under channel 02 fluorescence, after the default area mask had
been adjusted to around 75%. This was more sensitive at capturing microparticles
than the bright field as significant haloing contributes to the sample fluorescence,
augmenting the signal. Other parameters, such as diameter and perimeter were
determined by addition to the features list, after adjusting themask in channel 02 to fit
tightly around the event. To analyze the number of microparticles generated over the
45-minute sample acquisition, all events falling in the microparticle gate were plotted
on a scatter graph showing time versus objects/sec. Each plot was manually adjusted
so that the machine noise generated at the beginning of acquisition was set to zero,
allowing determination of the rate of microparticle production over time, regardless
of the number of microparticles that were already present within the sample.
Statistical analysis. Statistical analysis was carried out using SPSS 22 (IBM). Mixed-
model ANOVA was used for microparticle generation, One-way repeated measures
ANOVA with Bonferroni post-test was applied to number of microparticles gener-
ated from neutrophils during stimulation with stimuli. Two-way repeated measures
ANOVA with Bonferroni post-test was applied during cytoskeletal inhibition
experiments. A P value of ,0.05 was considered significant.
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